Search | IOVS | ARVO Journals

Showing 1 – 20 of 106

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2025

Vitreous Abnormalities in Retinitis Pigmentosa

Hossein Ameri; Zainab Rustam; Folahan Ibukun; Nieraj Jain; Ian Han; Sandeep Grover; Shivani Kochhar; Vinit B Mahajan; Hailey Ahrens; Roxanna Rabiee; Sandra Montezuma; Nancy Aychoua; Sun Young Lee; Rupert Strauss; Laura Kuehlewein; Peter A Campochiaro; Xiangrong Kong

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):1942.

ARVO Annual Meeting Abstract June 2025

Evaluation of tyrosine kinase inhibitor release from ethylene-vinyl acetate-based suprachoroidal implants in minipig eyes

Atul Garkal; Harsh Patel; Jikui Shen; Joshua de Souza; Mingliang Zhang; Raquel Lima e Silva; Sean Hackett; Gerald Ferrara; Edward Dobrzykowski; Cyonna Holmes; Jeffrey C Haley; Peter A Campochiaro; Kunal S Parikh

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):4326.

ARVO Annual Meeting Abstract June 2025

Efficient Retinal Transduction and Excellent Inhibition on Retinal Detachment of EXG202 in NHP and a Severe Neovascular Leakage Mouse Model

GUOJIE YE; Jikui Shen; Li Dai; Shuyuan Chen; Chunjuan Song; Mingliang Zhang; Zhenhua Wu; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):508.

ARVO Annual Meeting Abstract June 2025

Lens Abnormalities and Associated Risk Factors in Retinitis pigmentosa – Baseline Data from the NAC Attack Clinical Trial

Laura Kuehlewein; Folahan Ibukun; Yanzhao WANG; Michel Michaelides; Sandeep Grover; Shivani Kochhar; Zainab Rustam; Hossein Ameri; Richard N Sather; Mandeep S Singh; Nancy Aychoua; Rupert Strauss; Sandra Montezuma; Peter A Campochiaro; Xiangrong Kong

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):3141.

ARVO Annual Meeting Abstract June 2025

Factors associated with microperimetry false positive responses in patients with retinitis pigmentosa (RP)

Rachel M Huckfeldt; Yanzhao WANG; Ahmad al-Moujahed; Kirill Zaslavsky; Hossein Ameri; Nancy Aychoua; Artur V Cideciyan; Thales A C de Guimarães; Jacque L Duncan; Sandeep Grover; Folahan Ibukun; Nieraj Jain; Robert K Koenekoop; Byron L Lam; Michel Michaelides; Kristina Pfau; Zainab Rustam; Peter A Campochiaro; Xiangrong Kong

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):1941.

ARVO Annual Meeting Abstract June 2025

Endogenous Levels of N -acetylcysteine in Human Plasma in the NAC Attack Study

Alyssa C. Bonnell; Jennifer R Chao; Yanzhao WANG; Hailey Ahrens; Hossein Ameri; Nancy Aychoua; Theo de Boer; Abby T Fahim; Dana Frank; Alexandra Viviann Garafalo; Sandeep Grover; Rachel M Huckfeldt; Robert B Hufnagel; Folahan Adesola Ibukun; Robert K Koenekoop; Jennifer I Lim; Mary McCormick; Zainab Rustam; Richard N Sather; Aliya Siddiqui; Peter A Campochiaro; Xiangrong Kong

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):3150.

ARVO Annual Meeting Abstract June 2025

Real-World Efficacy and Safety of the Ranibizumab Port-Delivery System in Neovascular AMD: First Time Two-Year Results of the SUMMIT Study

Humza Sulahria; Hannah Khan; Aamir Abdul Aziz; Huma Khan; Jordyn Vannavong; Fawad Razai; David RP Almeida; Sean Nguyen; Dante Joseph Pieramici; Anam Akhlaq; Peter A Campochiaro; David Aaron Eichenbaum; Jordan M Graff; Nancy Holekamp; John Kitchens; Jeremy Wolfe; Greggory Gahn; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):4112.

Retina April 2025

Structural Updates to the Implant and Refill Needle of the Port Delivery Platform

PDF

Dante J. Pieramici; Peter A. Campochiaro; Margaret Chang; Ian Pearce; Carl D. Regillo; Shamika Gune; Nancy Holekamp; Carlos Quezada-Ruiz; Shrirang V. Ranade; Natasha Singh; Geoffrey Wise; Joshua Horvath
TAGS: implants, needles
Trans. Vis. Sci. Tech.. 2025; 14(4):8. https://doi.org/10.1167/tvst.14.4.8

Includes: Multimedia, Supplemental Content

ARVO Annual Meeting Abstract June 2024

Port Delivery System With Ranibizumab (PDS) in diabetic macular edema (DME): additional primary analysis results of the phase 3 Pagoda trial

Varun Malhotra; Michael A. Klufas; Dennis M Marcus; Jordan M Graff; Peter A Campochiaro; Salman Rahman; Paul Latkany; Shamika Gune; Stephanie DeGraaf; Ashwini Bobbala; Mel Rabena; Carlos Ruiz; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6233.

ARVO Annual Meeting Abstract June 2024

Suprachoroidal Gene Transfer with Nonviral Nanoparticles in Large Animal Eyes

Mingliang Zhang; JIkui Shen; Raquel Lima e Silva; Kathryn Luly; Sean Hackett; Stephany Tzeng; Shirley Lowmaster; Sydney Shannon; David Wilson; Jordan Green; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2228.

ARVO Annual Meeting Abstract June 2023

Reproducibility of ellipsoid zone (EZ) parameters measured under different OCT scan settings in retinitis pigmentosa (RP)

Xiangrong Kong; Kevin Choy; Muhammad Khan; Yuchen Lu; Dagmar Wehling; Peter A Campochiaro; Glenn J Jaffe

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4659.

ARVO Annual Meeting Abstract June 2023

Efficacy Evaluation of EXG102-031, A Novel AAV-based Gene Therapy for Neovascular AMD in a Mouse Model of VEGF-A-induced Exudative Retinal Detachment vascular leakage Mouse Model

GUOJIE YE; Jikui Shen; Li Dai; Raquel Formica; Lijun Wang; Zhenhua Wu; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1916.

Lecture November 2021

Retinal and Choroidal Vascular Diseases: Past, Present, and Future: The 2021 Proctor Lecture

PDF

Peter A. Campochiaro
TAGS: ischemia, pathogenesis, retinal diseases, vascular diseases, vascular endothelial growth factor a, injections, diabetic retinopathy, hypoxia
Invest. Ophthalmol. Vis. Sci.. 2021; 62(14):26. https://doi.org/10.1167/iovs.62.14.26

ARVO Annual Meeting Abstract June 2021

The design and patient acceptability of NAC Attack a phase-3 clinical trial for retinitis pigmentosa (RP)

Xiangrong Kong; Susie trotochaud; Fahd Naufal; Peter A Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3543.

ARVO Annual Meeting Abstract June 2021

Pharmacokinetic profile of the Port Delivery System with ranibizumab (PDS) in the phase 3 Archway trial

Peter A Campochiaro; Shamika Gune; Mauricio Maia; Han Ting Ding; Katie Maass

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):350.

ARVO Annual Meeting Abstract June 2021

Suppression of Murine Choroidal and Retinal Neovascularization by Risuteganib and the Accompanying Transcriptome Changes in the OIR Retina

Zixuan Shao; Sean F. Hackett; Raquel Formica; Yogita Kanan; Dan Zhou; John Y Park; Hampar L Karageozian; Vicken H Karageozian; Peter A Campochiaro; Julia A. Kornfield

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):186.

ARVO Annual Meeting Abstract June 2021

Prediction of Best-Corrected Visual Acuity from Optical Coherence Tomography in Patients with Neovascular Age-Related Macular Degeneration Using Deep Learning

Anam Akhlaq; Saleema A. Kherani; Craig Jones; Peter A Campochiaro; Tin Yan Liu

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):131.

ARVO Annual Meeting Abstract June 2020

Pharmacokinetic (PK) Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 2 Ladder Trial

Peter A Campochiaro; Shamika Gune; Mauricio Maia; Katie Maass

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1157.

ARVO Annual Meeting Abstract June 2020

Macular function response to N-acetylcysteine Treatment in patients with Retinitis Pigmentosa

Grace Tsai; Peter A Campochiaro; Xiangrong Kong

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1909.

ARVO Annual Meeting Abstract June 2020

Classification of disease severity in Retinitis Pigmentosa

Bushra Usmani; Mustafa Iftikhar; Marili Lemus; Peter A Campochiaro; Jose Alain Sahel; Hendrik P Scholl; Syed Mahmood Ali Shah

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3024.

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Filters

Specify Date Range

Vitreous Abnormalities in Retinitis Pigmentosa

Evaluation of tyrosine kinase inhibitor release from ethylene-vinyl acetate-based suprachoroidal implants in minipig eyes

Efficient Retinal Transduction and Excellent Inhibition on Retinal Detachment of EXG202 in NHP and a Severe Neovascular Leakage Mouse Model

Lens Abnormalities and Associated Risk Factors in Retinitis pigmentosa – Baseline Data from the NAC Attack Clinical Trial

Factors associated with microperimetry false positive responses in patients with retinitis pigmentosa (RP)

Endogenous Levels of N -acetylcysteine in Human Plasma in the NAC Attack Study

Real-World Efficacy and Safety of the Ranibizumab Port-Delivery System in Neovascular AMD: First Time Two-Year Results of the SUMMIT Study

Structural Updates to the Implant and Refill Needle of the Port Delivery Platform

Port Delivery System With Ranibizumab (PDS) in diabetic macular edema (DME): additional primary analysis results of the phase 3 Pagoda trial

Suprachoroidal Gene Transfer with Nonviral Nanoparticles in Large Animal Eyes

Reproducibility of ellipsoid zone (EZ) parameters measured under different OCT scan settings in retinitis pigmentosa (RP)

Efficacy Evaluation of EXG102-031, A Novel AAV-based Gene Therapy for Neovascular AMD in a Mouse Model of VEGF-A-induced Exudative Retinal Detachment vascular leakage Mouse Model

Retinal and Choroidal Vascular Diseases: Past, Present, and Future: The 2021 Proctor Lecture

The design and patient acceptability of NAC Attack a phase-3 clinical trial for retinitis pigmentosa (RP)

Pharmacokinetic profile of the Port Delivery System with ranibizumab (PDS) in the phase 3 Archway trial

Suppression of Murine Choroidal and Retinal Neovascularization by Risuteganib and the Accompanying Transcriptome Changes in the OIR Retina

Prediction of Best-Corrected Visual Acuity from Optical Coherence Tomography in Patients with Neovascular Age-Related Macular Degeneration Using Deep Learning

Pharmacokinetic (PK) Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 2 Ladder Trial

Macular function response to N-acetylcysteine Treatment in patients with Retinitis Pigmentosa

Classification of disease severity in Retinitis Pigmentosa

To View More...

You must be signed into an individual account to use this feature.